ReproCell

ReproCell Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of ReproCell (4978.T) as of Oct 19, 2026 is 40.38. In the previous year, Cash Conversion Cycle (CCC) was 94.52 — a change of -57.28% (lower).

Cash Conversion Cycle

40.38

YoY

-57.28%

Last updated:

Cash Conversion Cycle (CCC) of ReproCell is 2026 40.38 . Cash Conversion Cycle (CCC) of ReproCell was 2025 94.52 . It decreases by -57.28% lower compared to the previous year.

The ReproCell Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
139.16 JPY
Jan 1, 2020
129.17 JPY
Jan 1, 2021
121.85 JPY
Jan 1, 2022
48.26 JPY
Jan 1, 2023
60.55 JPY
Jan 1, 2024
84.87 JPY
Jan 1, 2025
94.52 JPY
Jan 1, 2026
40.38 JPY
The ReproCell Cash Conversion Cycle history
YEARCash Conversion CycleYoY
40.38-57.28%
94.52+11.37%
84.87+40.16%
60.55+25.47%
48.26-60.40%
121.85-5.66%
129.17-7.18%
139.16+4.85%
132.73+0.84%
131.62+10.01%
119.64-59.00%
291.81+224.29%
89.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Cash Conversion Cycle (CCC) of ReproCell is 40.38 in 2026.

Cash Conversion Cycle (CCC) of ReproCell changed from 94.52 to 40.38, representing a -57.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) ReproCell since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ReproCell

All Key Metrics — ReproCell